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Chikungunya virus (CHIKV) is a positive-sense, enveloped, single-stranded RNA 
virus belonging to the Alphavirus genus. Our studies identified that alphavirus 
nonstructural protein-3 (nsP3) phosphoprotein includes a macrodomain (MD) which binds 
and removes ADP ribose groups from mono ADP ribosylated substrates. As a post-
translational protein modification, ADP ribosylation transfers ADP ribose from NAD+ to 
the targeted protein by ADP-ribosyltransferases known as poly ADP ribose polymerases 
(PARPs). To determine the role of the alphavirus nsP3 MD (nsP3MD) ADP ribose-binding 
and hydrolase activities in viral infection, CHIKVs with point mutations in the nsP3MD were 
generated and used to infect C8-D1A murine astrocytes. The G32S mutant has less 
binding and hydrolase activities, while the Y114A mutant has more binding but less 
hydrolase activities, as compared to wildtype (WT). Infection induced little or no ADP 
ribosylation of proteins in astrocytes, although there was increased interferon-stimulated 
PARP gene expression. The G32S mutant was less efficient at initiating infection and 
making replication complexes than WT virus. Production of viral RNA, nonstructural 
proteins (nsPs), and infectious virus by G32S was decreased compared to WT at early 
time points. The Y114A mutant was also less efficient at initiating infection but had a 
higher number of dsRNA positive cells compared to WT. Levels of Y114A RNA, nsPs, 
and infectious virus were the same or higher compared to WT. However, in contrast to 
observations for infection in neuronal cells, in astrocytes the nsP3MD mutants made more 
structural proteins than WT. In addition, CHIKV infection induced production of type I IFN 
in astrocytes, but, inhibition of type I IFN signaling did not affect virus replication. 
Therefore, ADP ribosyl hydrolase and binding activities of the alphavirus nsP3 MD are 
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critical for viral replication in astrocytes as well as neurons, but cellular responses are 
distinct. To further compare CHIKV-mediated innate immune signaling pathways, NSC34 
neuronal cells that do not produce IFN and C8 astrocytic cells that do produce IFN were 
infected with CHIKV WT. RIG-I like receptors (RLR) and toll-like receptors (TLRs) were 
tested, and RLRs were identified as the key innate immune pathway inducing type I IFN 
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1.1 CHIKV: Epidemiology, Clinical Manifestation, and Neurovirulence 
Epidemiology 
 Chikungunya virus (CHIKV) is a member of the Alphavirus genus in the 
Togaviridae family (1,2). Alphaviruses are small, spherical, enveloped, and positive 
sense, single-stranded ribonucleic acid (RNA) viruses (1,2,3). As chikungunya is a 
mosquito-borne virus, the current expansion of mosquito vectors into new geographical 
regions brings public health concerns over the world (2,4). The two major mosquito 
species that transmit CHIKV are Aedes aegypti and Aedes albopictus and global maps 
of their distribution show that they are located mainly in tropical and subtropical regions 
(Fig. 1.1) (5). This distribution matches the countries and territories where chikungunya 
cases have been reported (Fig. 1.2) (6). 
Since the first discovery of CHIKV at Makonde Plateau in 1952 near Tanzania, 
limited but continuous spillover events from sylvatic cycles into humans in Southeast Asia 
and Africa have been reported, (7,8) but the routes of transmission were unidentified. 
However, investigations of two major outbreaks in Kenya and Comoros, confirmed Aedes 
aegypti as the main vector of CHIKV (8). In 2005, CHIKV causing the outbreak on La 
Reunion island possessed a mutation in the E1 glycoprotein that increased its new vector 
adaptability (9). Introduction of the E1-A226V mutation facilitated infection of Aedes 
albopictus, a more widespread vector for transmission of CHIKV to human populations 
(8,10). 
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While the virus adapted to this additional vector species, human movement, 
climate changes, and urbanization further exacerbated the spread of CHIKV throughout 
the world. Human movements associated with trade and travel introduced these vectors 
to new regions such as Europe and the Americas (11). Climate change with global 
warming made the temperate climate zone a more suitable tropical region for the 
reproduction of vectors (11). Simultaneously, urbanization helped anthropophilic Aedes 
species to adapt and spread across the continents (12).   
Currently, CHIKV has affected more than 50 countries and 2 million suspected 
cases have been reported (13). Two countries with recent outbreaks were Brazil and 
Thailand. Although travel-associated cases occurred, few countries had endemic 
transmission in 2019 (14). However, as the vectors spread surveillance for CHIKV needs 
to be maintained. 
Clinical Manifestation 
The incubation period of CHIKV is usually 2-12 days (15,16) and rates of lab 
confirmed asymptomatic CHIKV cases ranged from 3.8% to 27.7% (15). These rates of 
asymptomatic CHIKV are lower than those of the other mosquito-borne viruses (16) 
although symptoms for many patients are mild. Typically, chikungunya fever is 
characterized as an abrupt onset of fever, polyarthralgia, and rash with fatigue (16,17). 
Around 90% of symptomatic cases have polyarthralgia affecting the joints of ankles, 
wrists, and knees (16,17). A rash on the arms and trunk is another characteristic symptom 
occurring in around 50% of confirmed cases. The rash is identified within 2-5 days of 
infection and resolves within 2 weeks (15, 18), but arthritis can become chronic. Virus 
may persist and induce continuous secretion of IL-6 as well as CHIKV-specific IgG (16, 
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19, 20). Therefore, most CHIKV infections are not fatal, but patients with other risk factors 
such as diabetes and cardiovascular diseases can develop more severe disease (15-21, 
22). 
Neurovirulence 
 Mutations in the viral genome can result in changes in virus phenotypes, host 
reservoirs, and tissue tropism leading to altered virulence. During the 2005-2006 Reunion 
Island outbreak, 25% of patients reported neurologic symptoms (22). While the Old-World 
CHIKV is not usually associated with encephalitis, some patients developed encephalitis, 
encephaloneuropathy, Guillain-Barré syndrome, and stroke (23,24). Neurovirulence of 
this reemerged CHIKV resulted in long term of sequelae of infection that affected the 
health and well-being of infected patients.  
Mechanisms of alphavirus neurovirulence are either through virus-induced cell 
death or inflammatory damage to the central nervous system (CNS) (25). Most 
encephalitic alphaviruses do not cause neurologic disease because innate and adaptive 
immune responses control and clear the virus before brain entry (25). However, when 
neurotropic viruses replicate in peripheral organs to maintain a high level of viremia, CNS 
invasion across the blood brain barrier can occur by way of infected leukocytes or 
cerebrospinal fluid CSF entry (25). In CHIKV-infected patients with neurological disease, 
virus could be isolated from the CSF, and viral RNA could be amplified by RT-PCR to 
confirm this potential route of CNS entry (22).  
In vivo studies showed that astrocytes are the main target cells for CHIKV in the 
human brain although oligodendrocytes and neurons are also susceptible to infection (26, 
27, 28). Histopathology demonstrated that newly isolated Asian and East, Central, and 
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South African (ECSA) strains infected mice by traversing the blood-CSF barrier, with 
localization to astrocytes and neurons (27). The main functions of astrocytes are to 
maintain homeostasis of the brain and modulate levels of ions, neurotransmitters, and 
gliotransmitters (29). Because astrocyte end feet are in close contact with endothelial 
cells of the blood-brain barrier, they are exposed to virus infection (29). Upon infection, if 
astrocytes cannot clear the virus, they can transmit the virus to other CNS cells that may 
result in cell death due to apoptosis or necrosis. 
In response to CHIKV infection, astrocytes activate the pro-apoptotic gene, 
eIF2ɑK2 (70) to induce apoptosis. In vitro studies have demonstrated that CHIKV-infected 
astrocytes upregulate the mRNA levels of other proapoptotic factors, such as TNF-ɑ, 
FasL, and lymphotoxin B (28). Astrocytes activate the caspase-9 apoptotic programmed 
cell death pathway (28). When astrocytes continuously produce virus, proteins are 
processed for presentation to CD8+ T cells as targets for cytolysis (25). Both clearance 
pathways cause death of unreplaceable infected cells and acute neurological disease. 
For other alphaviruses, antibody-mediated long-term virus control is necessary to prevent 
neurologic disease due to reactivation (30). Therefore, it is optimal to clear the virus 
before it infects the CNS. 
 5 
 
Figure 1.1 Global Map of the Predicted Distribution of A) Aedes aegypti and B) 
Aedes albopictus. The colors of the map express the frequency of the distribution, and 
black dots represent the distribution of the occurrence of each species.  Image was 






Figure 1.2: CHIKV Cases Reported: Countries and Territories. Geographical 
distribution of CHIK cases and outbreaks over the world. Countries are mainly located in 
North and South America, Southeast Asia, Africa, and Southern Europe. The image was 
















1.2 CHIKV: Genome, Structure, and Replication Cycle 
Genome 
CHIKV is a member of the alphavirus family of arthropod-borne, positive-sense, 
single-stranded RNA viruses (1, 2, 3, 22). Other pathogenic human alphaviruses include 
Sindbis virus (SINV), western, eastern and Venezuelan equine encephalitis viruses 
(WEEV, EEEV, and VEEV), and Ross River virus (1, 31). As alphaviruses share common 
characteristics, important research from other investigators has contributed to our current 
understanding of the genome, structure, and replication process of CHIKV. 
The genome size is about 11,800 bases and composed of two open reading 
frames (ORFs) (32). The first ORF encodes a polyprotein P1234, which is cleaved into 
four different non-structural proteins (nsPs) by the autoproteolytic activity of nsP2 to form 
the fully functional and versatile replicase enzymes required for the replication process 
(Fig. 1.3) (32, 33). The second ORF as a subgenomic RNA encodes another polyprotein 
that includes the 3 main structural proteins (capsid, E1, E2) and three small peptides (E3, 
TF and 6K) (32,33,34). 
There are 5’ and 3’ untranslated regions (UTR) and a junction between the two 
ORFs. The lengths of the 5’ UTRs differ among alphaviruses. The 5’ end has a type 0 5’ 
cap structure (N7mGppp) to stabilize the virion genome and facilitate translation of viral 
proteins for replication (35). The 5’ UTR is recognized by host translational factors (eIF4E 
and eIF4F) to form the distinct secondary structure for translation of the nonstructural 
polyprotein (35). The 5’ UTR of the subgenomic RNA does not require eIF4G or eIF2 for 
translation initiation of the structural proteins and thus escapes host-translation shut off 
by PKR activation as part of the innate immune response (35,36). At the 3’ end, there is 
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a poly (A) tail to support negative strand RNA synthesis and efficient translation (35). At 
least 11-12 residues are required in the 3’UTR to interact with the RNA recognition motifs 
of poly (A)-binding protein (36). Like the 5’ UTR, the length of the 3’ UTR for each 
alphavirus is different. While host cellular miRNA targets 3’ UTR of CHIKV as an immune 
response, CHIKV can adapt to evade the cellular response with mutations in the 3’ UTR 
regions selected to eliminate binding sites (35, 37).  
Structure 
Numerous research projects have studied 3D structures of alphaviruses through 
cryogenic electron microscopy and crystallization of component proteins since the 1990s 
(1). Based on recent studies with more advanced technologies, one copy of the 11.8Kb 
genome and surrounding capsid proteins form icosahedral nucleocapsid structures to 
protect its viral RNA. These structures are covered by an envelope containing 
glycoproteins embedded in a lipid bilayer (1). For each virion 240 Immature E1 and pE2 
glycoprotein heterodimers are synthesized In the endoplasmic reticulum within the lipid 
bilayer (38). Between the pE2 and E1 heterodimer, there are 6K proteins to regulate ion 
permeability between the environment and the virus (39). As viroporins, 6K proteins help 
virus release through budding and membrane permeability at the host cell plasma 
membrane (39). Host furin cleaves pE2 into E2 and E3 during Golgi transport (40). E1 
and E2 heterodimers form mature trimeric spikes at the virus surface. The E1 glycoprotein 
is responsible for the fusion of virus membrane and host membrane, while E2 
glycoproteins bind host receptors and stimulate receptor-mediated endocytosis (1, 40). 
Replication Cycle 
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 Most alphaviruses utilize E2 glycoproteins for binding to host receptors and 
receptor-bound virus particles are predominantly internalized through clathrin-mediated 
endocytosis (Fig. 1.4) (13, 41). siRNA screening in the human osteosarcoma U2OS cell 
line demonstrated that the silencing of clathrin blocked CHIKV entry (42). During virus 
binding, glycosaminoglycans and TIM1 within the host membrane work as attachment 
factors (13, 41). As glycosaminoglycans are present in most cell types, CHIKV does not 
show cell type-specificity (13) and even without known attachment factors, CHIKV still 
can infect many types of host cells.  
CHIKV fusion with endosomes is cell type-dependent. In C6/36, a mosquito cell 
line (Ae. albopictus salivary gland), CHIKV fuses with both Rab5-positive early 
endosomes and Rab7-positive late endosomes (41, 43, 44). However, in HEK 293T 
human epithelia cells, CHIKV fusion is dependent only on early endosomes (44). Because 
of conformational changes at low pH, the virus envelope and endosomal membrane fuse 
and deliver the virus genome into the cytoplasm (13). The virus genome is directly 
translated by hijacking host translation factors to synthesize a polyprotein nsP1234 
followed by regulated nsP2 cleavage of the polyprotein to nsP1, nsP2, nsP3, and nsP4 
(13). As nsP4 is the RNA dependent RNA polymerase, all replicase enzymes assemble 
with the viral genome to recruit host factors and form RNA replication complexes (45). 
Following synthesis of newly made positive-sense viral RNA, RNA replication complexes 
exponentially increase until all cytosolic host factors are in use for viral RNA replication 
(45). The dsRNA intermediates within RNA replication complexes are surrounded by a 
double membrane spherule to evade detection by the host innate immune response 
(13,45). When adequate numbers of nsPs are transcribed and translated, translation of 
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subgenomic RNA (2nd ORF) for the synthesis of the structural polyprotein begins (45). 
Capsid is autocatalytically cleaved from the glycoproteins that are then processed by host 
enzymes in the ER. Post-translational modification, such as palmitoylation and 
glycosylation matures E1 and pE2 heterodimers into fully developed spikes (13). Furin 
cleaves pE2 between E3 and E2 in the Golgi (13). There are two ways for CHIKV to be 
released from infected cells. First, the spikes are delivered to the plasma membrane, and 
nucleocapsids interact with the envelope spikes to bud out directly to the extracellular 
space (46). Second, capsids and spikes can be assembled within vesicles and delivered 
















Figure 1.3: Genome Structure of CHIKV. The CHIKV genome includes two open 
reading frames, a 5’ cap, and a 3’ poly (A) tail.  Genomic mRNA and subgenomic mRNAs 
are produced. Genomic mRNA is translated to produce a polyprotein that is cleaved into 
four non-structural proteins (nsP1, nsP2, nsP3, and nsP4). Subgenomic mRNA encodes 
five structural proteins: capsid, two glycoproteins (E2 and E1), and three small peptides 
(E3, TF and 6K). The image is adapted from Singh, S. K., & Unni, S. K., Medical Virology, 
2015 (32). 
 
Figure 1.4: Replication Cycle of CHIKV. CHIKV E2 proteins bind host cell receptors 
and clathrin-mediated endocytosis brings the virion into the cell. Low pH in acidified early 
endosomes induces a conformational change in the glycoprotein spikes and fusion of E1 
proteins with the endosomal membrane to deliver the viral genome to the cell cytoplasm. 
After the translation of nsPs from genomic RNA, replication complexes are formed at the 
plasma membrane to produce viral RNAs. Subgenomic RNA is translated to produce the 
structural proteins required to assemble new virus particles. After packaging, viruses 
either bud out or egress out as a large vesicle. The image is adapted from Silva, L. A., & 
Dermody, T. S, The Journal of clinical investigation, 2017 (13). 
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1.3  Immune response to CHIKV infections 
Host antiviral defenses include the innate and the adaptive immune responses (47). 
The mammalian innate immune response is initiated by sensing the presence of the virus. 
It both inhibits viral replication and alerts the adaptive immune response (47). Both type I 
interferon and inflammatory cytokines play important roles in the innate immune 
response. The mammalian adaptive immune response targets specific viral antigens and 
involves the participation of dendritic cells, T cells, and B cells (48). Specific 
immunoglobulins, cytokines and effector activities of B and T cells are the main results of 
adaptive immune responses (48). 
Pattern recognition receptors (PRRs) are the frontline of innate immune response 
recognition of pathogen-associated molecular patterns to sense the existence of the virus. 
PRRs can be either immune sensing receptors or sensing and effector receptors (49). 
Immune sensing receptors are Toll-like receptors (TLRs), RIG-I like receptors (RLRs), 
NOD-like receptors (NLRs) and cyclic CMP-AMP synthase (cGAS) that sense viral 
genomes or proteins. After cell entry at the endosome, endosomal TLRs (TLR3, 7, 8, and 
9) can recognize dsRNA, ssRNA, and CpG DNA viral genomes (49). TLR2 and 4 can 
also detect viral structural proteins at the plasma membrane and activate the adaptor 
protein TIRAP (50). All TLRs except TLR3 signal through the MyD88 and TRAF6 pathway 
to activate NF𝛋B (84). TLR3 signals through its own TRIF/TRAM pathway to 
phosphorylate interferon regulatory protein (IRF) 7 to activate both IFN and NF𝛋B 
pathways (50).  
Both intracellular MDA5 and RIG-I RLRs are RNA helicases recognizing long 
dsRNA and 5’triphosphate RNA, which are unusual molecules in uninfected cells. 
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Following RNA recognition, RLRs interact with MAVS as its adaptor protein and activate 
tank-binding kinase 1 (TBK1) to phosphorylate IRF3 early and activate both IRF3 and 
IRF7 at later time points. Activation of IRF3 and IRF7 induces production of mRNA for 
type I IFN. NLRs can recognize ssRNA to cause inflammasome and caspase 1 activation 
(49, 51). NLRP3 induced through the NF𝛋B pathway and pro IL1β form inflammasomes 
that can activate caspase 1 to release IL1β and IL18 (49). cGAS can recognize viral DNA 
in the cytosol and interact with STING to activate TBK and the IFN producing pathway 
(48).  
Protein kinase PKR is a sensing and effector receptor binds to long viral dsRNA 
and phosphorylates translation initiation factor eIF2α. eIF2α is a recyclable protein 
translation factor but, phosphorylation prevents reuse and thus inhibits protein translation 
(51). This inhibition is efficient for both viral and cellular protein translation unless viral 
evasion mechanisms exist.  
RLRs, TLRs, and PKR are the main receptors detecting CHIKV ssRNA and dsRNA 
(Figure 1.5) (50). TLR7 and 8 can recognize viral positive ssRNA to activate the 
Myd88/TRAF6 pathway and phosphorylate IKKβ and I𝛋B. NF𝛋B signaling controls mRNA 
transcription for production of antiviral cytokines (48, 51). TLR3 can recognize CHIKV 
intracellular dsRNA produced by replication complexes. Recognition of dsRNA can 
activate both type I IFN and NF𝛋B pathways. In animal studies, TLR3 knockout mice 
infected with CHIKV had increased viremia, infected macrophages and neutrophils, and 
reduced CD4+ T cells (85). Therefore, TLR3 is involved with recognition of virus and 
reduction of viremia. 
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Both intracellular MDA5 and RIG-I RLRs limit CHIKV replication and initiate type I 
interferon production, mainly IFNβ at early time points (47). IRF3 is the initial regulator of 
anti CHIKV responses downstream of RLRs. Phosphorylation and activation of IRF3 
results in the induction of immediate early IFN mRNA and synthesis of IFNβ. Early IFNs 
can act in an autocrine or paracrine manner to induce synthesis of more IFNβ, IFNαs, 
and antiviral proteins (48). Type I interferon receptors signal to synthesize and activate 
IRF7. Activated IRF7 and IRF3 together induce synthesis of more antiviral proteins (48, 
49). Without IRF7, CHIKV-infected mice could not induce type I IFN, and type I IFNs were 
not detected in serum (53). IFNα and IFNβ (together as Type I IFN) bind to cell surface 
receptors to activate the JAK/STAT pathway to induce expression of IFN-stimulated 
genes (ISGs) (54).  Two host defense ISGs against CHIKV infection are major 
histocompatibility (MHC) class I and ISG15. When more MHC class I proteins are 
synthesized in the endoplasmic reticulum, more processed viral peptides bind to MHC 
class I and are transported to the cell surface to interact with CD8+ T cells (54). ISG15 
inhibits viral release by blocking virus budding (55). ISG15 knockout mice are more 
susceptible to CHIKV with increased mortality (56). Thus, for early detection of CHIKV, 
type I IFN is an essential element of the innate immune response. 
For the innate cellular immune responses, upon CHIKV infection, astrocytes 
produce inflammatory chemokines CCL2 and CCL7 in response to NF𝛋B-induced IL1β 
and TNFα (57). CCL2 and CCL7 recruit macrophages to replication sites where they 
produce IL6, TNFα and GM-GSF to counter CHIKV infection. Another type of recruited 
macrophage expresses M2-associated proteins to help tissue repair for apoptosis but 
also can become a reservoir for CHIKV (57). Natural killer (NK) cells are also recruited to 
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CHIKV-infected tissues to produce perforin and cause cytolysis before CD8+ T cells arrive 
at the site (57). NK cells also secrete IFN𝛄 and TNFα to activate macrophages and induce 
more Class II MHC to bridge innate and adaptive immune responses. 
The adaptive immune response to CHIKV infection can both protect and destroy 
host cells. In mouse models as virus titers reach peak levels, within 7 days CD8+ T cells 
come to infected sites (58). However, knock out of CD8+ T cells did not increase CHIKV 
viremia or the degree of subcutaneous disease compared to WT demonstrating that CD8+ 
T cells did not efficiently clear virus, but rather caused death of infected cells. CD4+ T 
cells contributed significantly more to reduction of viremia and disease (57, 58). The most 
effective adaptive immune response to eliminate circulating infectious CHIKV was 
antibody. Antibody neutralizes CHIKV by binding to the trimer spikes of glycoprotein 
heterodimers (57). Both innate cellular immune response and adaptive immune 
responses inefficiently destroy host cells causing subcutaneous and neurologic disease. 
Therefore, inducing Type I IFN is extremely important for early detection of virus leading 
to antibody production.  
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Figure 1.5 TLR, RLR, NLR Innate responses. For antiviral defense, host cells have 
innate immune response signaling pathways. RLRs and TLRs are the main innate 
immune pathways that induce transcription of the type I IFN gene. After translation of type 
I IFN, interferon stimulated genes are produced that inhibit virus replication within cells. 




1.4 Alphavirus Neurovirulence: nsP3, Viral MD, ADP Ribosylation, and PARPs 
nsP3 
 The first ORF of CHIKV encodes 4 nonstructural proteins. nsP1 is an RNA capping 
enzyme with N-7methlytransferase and guanylyltransferase functions that protect the 
viral genome from degradation by host nucleases (59,60). nsP2 has helicase and 
protease activities. When dsRNA is made during replication and transcription, nsP2 
unwinds dsRNAs for further use. Simultaneously, nsP2 can cleave the viral nonstructural 
polyprotein into several functional replicase enzymes (1,13, 61). nsP4 is an RNA 
dependent RNA polymerase for the replication. However, the function of nsP3 is more 
enigmatic and it is the least understood of the nsPs. 
 Within alphaviruses, the size of nsP3 proteins range from 469 to 570 residues (62). 
nsP3 is composed of three different domains. Starting with N terminus, they are the 
macrodomain (MD), the alphavirus unique domain (AUD) (central zinc-binding domain), 
and the hypervariable domain (HVD) (Fig. 1.6). HVD is the most well-characterized and 
has the most variable sequences (62). One function of the CHIKV HVD is interaction with 
the Ras-GAP SH3 domain-binding protein (G3BP) 1 and G3BP2 to form stress granules 
(63). Initially, nsP3 is located within the replication complexes and later interacts with 
G3BP1 and G3BP2 (64,65,66). Stress granules can have both anti- and proviral activities 
(63). Viruses modulate stress granules to sequester their viral RNA with cell components 
and increase the replication efficiency (67). On the other hand, cells can recognize the 
existence of viral RNA with intracellular innate responses before viral protein translation 
and sequester translation initiation factors into the stress granules before viral proteins 
can be translated (67).  
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 Function of the zinc-binding domain, also known as the AUD, is poorly understood 
but has roles in genome replication (62). Viable AUD mutants cannot form normal 
replication complexes (62). AUD is connected to the MD by a linker to form a circle-like 
shape (62). 
Macrodomain 
 Macrodomain is a conserved protein fold that consists of 130-190 amino acids with 
a central beta-sheet enclosed by 4-6 alpha helices (68). MD was first identified in viruses 
as X-domains and renamed MD when it was recognized as the C terminal domain of 
histone macroH2A (68). This structure supports binding and processing of nucleotides 
and its active site accommodates ADP ribose (ADPr) and its derivates. The active site 
center binds to the substrate and has two binding-loops (69).  Loop 1 is the catalytic loop 
associated with hydrolase activity (68, 69), and loop 2 is the pyrophosphate-binding loop 
that further arranges substrate binding (Fig. 1.7) (68).  
The diverse functions of the MD are associated with the NAD+ signaling pathway, 
DNA repair mechanisms, redox balance, and response to viral infection (69). To rebuild 
NAD+ for signaling, the MDs interacts with NUDIX pyrophosphatases to recycle ADPr into 
AMP and ribose-5-phosphate (69,70). The MDs of polynucleotide kinase and 
polyphosphate hydrolase are associated with single-stranded DNA repair (69). While 
PARP1 adds ADPr after sensing DNA-damage, Poly-ADR glycohydrolases (PARG) can 
reverse poly ADPr gene regulation. Diverse proteins with MDs help cells to maintain 
homeostasis. 
 Macrodomains are conserved and found in all kingdoms of life. The viral MDs are 
found in a subset of positive sense ssRNA viruses in the families Myoviridae, 
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Coronaviridae, Togaviridae, and Hepesviridae (69, 70). The MDs of these virus families 
are in the macro D subclass and found in nsP3s. Viral MDs have two main functions 
important for virus replication and neurovirulence. They can dephosphorylate and 
deacetylate monomeric ADP-ribose (MAR) and its derivatives (68,71) and can bind and 
hydrolyze an ADP-ribose unit from MARylated proteins or the last ADP-ribose from poly 
ADP-ribosylated proteins (68,72,73,74). Mutations introduced to ADP-ribose binding sites 
did not affect replication in a non-neuronal cell line, but impaired replication in neuronal 
cells in vitro, and decreased neurovirulence for mice in vivo (72,73,74,75). Also, in 
alphavirus-induced encephalomyelitis, mutations affecting binding and hydrolase 
activities resulted in less virus replication and less clinical disease in mice (75). 
ADP-ribosylation 
ADP-ribosylation is a reversible post-translational modification with roles in 
signaling pathways, gene regulation, DNA repair, and apoptosis (76, 77). As a reversible 
modification, diverse enzymes regulate this protein modification and are described as 
writers, erasers, readers, and feeders of ADPr (78, 79). As ADP-ribose writers, ADP-
ribosyltransferases (ARTs) and poly (ADP-ribose) polymerases (PARPs) are the main 
enzymes to deliver mono or poly ADP-ribose units to substrates (76) and have roles in 
chromatin regulation, stress responses, viral infections and cancer (69). Substrates are 
not limited to proteins but also can be nucleotides, and any small biological molecules 
(76). The main target amino acids for ARTs and PARPs have either electrically charged 
or polar side chains (mainly arginine, lysine, aspartic acid, glutamic acid, serine, and 
asparagine) (76,77). PARG, ADPr hydrolase, MacroD1 and D2 subclasses of MDs are 
erasers of ADPr, some of which can hydrolyze ribose-ribose bonds and ester bonds 
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between ribose and negatively charged amino acids (80). Loss of eraser functions cause 
cell death and increase sensitivity to stress from DNA damage and pathogens (79). 
As ADP-ribose readers, the ADPr binding domain (ARBD) can bind to various 
forms of ADP ribose on substrates. MDs, PAR-binding domains, and PAR-binding zinc 
finger motifs are examples of ARBD (78). These ARBDs can identify ADP ribose 
monomers, junctions between PAR, and ADP-ribose oligomers. By reading the 
substrates of ADPr, domains can connect ADP-ribosylation and cellular events by 
recruiting new enzymes (78). NAD+ synthases are the feeders of ADPr and produce NAD+ 
from nicotinamide mononucleotide and ATP (78). Partners with PARP, NAD+ synthases 
have defined subcellular localizations, and PARPs recruit the synthases to substrates to 
receive NAD+ for their functions. 
PARPs 
Humans encode 17 PARPs, and enzymatically active PARP can either MARylate 
or PARylate target proteins. PARP1 and PARP2 function in DNA repair related to 
damaged bases and double strand breaks (78, 80) and, in response to cellular stress, 
these PARPs can initiate parthanatos (80). Both PARPs also respond to metabolic stress 
related to obesity and cancer (80). PARP1 and PARP2 knockout mice were tested for 
metabolic effects important for homeostasis (80). PARP1 deficiency aggravated diet-
induced and age-specific obesity (81).  PARP2 knockout mice had elevated energy and 
oxygen consumption, lipid oxidation, and were protected from obesity (80).  
PARPs are also involved in RNA biogenesis, processing, and trafficking (78, 82). 
During stress, RNA-rich stress granules are formed to control translation and mRNA 
stability (82). Regulation of stress granules by PARP5a, PARP12, PARP13.1, PARP13.2, 
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PARP14, and PARP15 was required to repress translation and degrade mRNA (78, 82). 
Ribosomal RNA synthesis is also linked to PARP activity. PARP1 binds TIP5 of newly 
synthesized chromatin and inhibits the ribosomal RNA genes from forming repressive 
heterochromatin (78). In drosophila, PARP can bind to rRNA transcription and help 
maintain the structural integrity of nucleoli (78). 
While PARP1 and PARP2 are poly PARP enzymes, PARP6, PARP10, and 
PARP16 are mono PARP enzymes used in diverse signaling pathways. During 
neurodevelopment, PARP6 is a regulator of hippocampal neuron development (83). 
While newly developed neural circuits were dependent on dendrite growth and branching, 
PARP6 promoted complexity during dendrite morphogenesis (83). PARP10 is a repressor 
of the NF𝛋B pathway. PARP10 not only prevents polyubiquitination of NEMO but also 
ADP-ribosylates NEMO (83). Therefore, PARP10 inhibits nuclear localization of NF𝛋B. 
PARP16 is the main enzyme to induce an unfolded protein response at the endoplasmic 
reticulum by controlling UPR pathways related to endonucleases (83).  
While PARPs have diverse cellular functions, some PARPs also have innate 
immune response antiviral activities (84). PARP13, the first known antiviral family 
member, degrades retroviral RNA and promotes TRAIL-mediated apoptosis in response 
to viral infection (85, 86). PARP family members also regulate interferon, a fundamental 
innate immune response. PARPs 1, 9, 12, 13, and 14 either promote expression of type 
I IFN or interferon-stimulated genes (ISGs) (Fig. 1.8) (87). PARP1 promotes NF𝛋B 
activation in macrophages. CHIKV uses macrophages as carriers to transmit virus to 
different cell types and activate NF𝛋B to induce proinflammatory cytokines (87). PARP9 
interacts with transcriptional factors to remodel chromatin and increase the expression of 
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certain ISG genes (87). PARP12 binds to the TLR3 adaptor protein TRIF to enhance 
NF𝛋B pathway gene expression (87). PARP13 can bind to the RLR downstream protein 
MAVS to initiate pathway activation (87), and PARP14 promotes IFN promoter acetylation 
to enhance Pol II binding (87). However, PARP10 has proviral activity and indirectly 


















Figure 1.6: CHIKV Genome and nsP3 Domains. nsP3 has three major domains: a 
highly conserved N-terminal macrodomain, a central zinc-binding region, and a poorly 
conserved highly phosphorylated C-terminal domain. The HVD interacts with many 
cellular proteins for virus replication and stress granule assembly, but the roles of the 
macrodomain and zinc-binding domain are less well characterized. The image is adapted 
from Götte, B., Liu, L., & McInerney, G. M, Viruses, 2018 (62). 
 
Figure 1.7: Macrodomain Structure. Macrodomain has a central beta sheet surrounded 
by 4-6 alpha helices. The center of the active site can bind to the side chain of the 
substrate. Two loops are associated with MD function. Loop 1 (catalytic loop) has 
hydrolase activity, and loop 2 (pyrophosphate-binding loop) stabilizes binding. The image 





Figure 1.8: PARPs Related Innate Immune Response. (A and B) PARP 1, 9, 12, 13, 
14 are antiviral PARPS related to the innate immune response with activation of type I 
IFN, ISG and NF𝛋B pathways. However, PARP7, 10, and 11 demonstrate proviral 
properties. The image is adapted from Fehr, A. R., Singh, S. A., Kerr, C. M., Mukai, S., 














1.5  Objectives of the Thesis 
Macrodomains (MD) are highly conserved protein folds that bind ADP ribose 
(ADPr). ADP ribosylation is a post-translational protein modification resulting from transfer 
of ADPr from NAD+ to substrates by ADP-ribosyl transferases known as poly ADP ribose 
polymerases (PARPs). Our lab previously identified that the MD of the alphavirus 
nonstructural protein-3 (nsP3) phosphoprotein not only binds but also removes ADPr 
groups from mono ADPr substrates, and that this hydrolase activity is necessary for viral 
replication in cells and virulence in mice (72). Also, studies of neuronal cells confirmed 
that ADP ribosylation of proteins and nsP3MD ADPr binding are necessary for initiation of 
alphavirus replication, while hydrolase activity facilitates amplification of replication 
complexes (73). 
Histopathology studies of CHIKV infection in a mouse model show that within the 
brain CHIKV preferentially infects astrocytes, ependymal cells, epithelial cells of the 
choroid plexus and neurons (28). There is increased expression of interferon-stimulated 
PARP mRNAs upon alphavirus infection in CNS tissues of mice and in astrocytic cells, 
whereas in neuronal cells PARP activation occurs to drive ADP ribosylation of proteins 
without increased mRNA expression. The main objective of this research project was to 
understand how the ADP ribosyl binding and hydrolase activities of CHIKV nsP3MD affects 
CHIKV replication in astrocytes, and how astrocytes differ from neurons in the induction 
or production of type I IFN.  
Objective 1: Determine the importance of CHIKV nsP3MD ADP ribosyl hydrolase and 
binding activities for viral replication in astrocytic cells. 
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Objective 2: Compare the responses to CHIKV infection of astrocytes (produce IFN) and 
























Role of ADP-ribosyl hydrolase and binding activities of chikungunya 
virus nsP3MD in astrocytic cells  
2.1 Introduction 
Chikungunya virus (CHIKV) is an enveloped, positive sense ssRNA Old World 
alphavirus, which is transmitted by mosquito vectors (1, 3). While CHIKV mainly causes 
rash and arthritis accompanied by fever, re-emerging strains in recent outbreaks have 
also caused encephalitis and other neurological diseases (15, 17). In vivo studies 
demonstrated that newly isolated CHIKV strains preferably traverse the blood-CSF barrier 
to infect the brain, with viral proteins localized in astrocytes and neurons (26, 27, 28). 
Astrocytes are specialized glial cells with diverse functions including formation of the 
blood-brain barrier structure, nutrient support to neurons, glutamate transport, and 
regulation of synaptic transmission (88). Astrocytic end feet are connected to endothelial 
cells of the blood-brain barrier and available for infection by CHIKV. CHIKV-infected 
astrocytes can activate defensive cell death pathways and CD8+ T cells can kill infected 
cells through Fas-Fas ligand signaling to prevent virus spread (88). Death of 
unreplaceable neurons during CHIKV infection causes acute neurological damage . 
However, the molecular mechanisms of CHIKV neurovirulence mediated mainly through 
astrocytes is poorly characterized. 
The 11.8kb genome of CHIKV encodes four nonstructural proteins and five 
structural proteins. The nonstructural proteins form the replication machinery and 
synthesize genomic and subgenomic RNA necessary for virus production (72). nsP1 is 
an RNA capping enzyme to protect the viral RNA and facilitate translation (59). nsP2 has 
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helicase and protease functions to unwind dsRNA during the replication and cleave the 
nonstructural polyprotein into individual proteins (1,13). nsP4 is an RNA-dependent RNA 
polymerase for synthesis of viral RNA. nsP3 is a phosphoprotein with ADPr-binding and 
hydrolase activities that help to establish and amplify replication complexes (72, 73, 74). 
nsP3 also disrupts stress granules to release translation initiation factors and increase 
virus production (63, 67). nsP3 is a determinant of neurovirulence, induces the formation 
of spherules at the plasma membrane and controls RNA synthesis in replication 
complexes (72, 74). 
Macrodomains (MD) are highly conserved protein folds that bind ADP ribose 
(ADPr). ADP ribosylation is a post-translational protein modification resulting from transfer 
of ADPr from NAD+ by ADP-ribosyltransferases known as poly ADP ribose polymerases 
(PARPs) (68). Viral MDs are in the macro D subclass and highly conserved in 
nonstructural protein 3 of the coronavirus and togavirus/alphavirus families of positive-
sense RNA viruses . The first identified function of viral MDs was dephosphorylation and 
deacetylation of MAR and its derivatives (68). Another function includes binding and 
hydrolysis of ADPr from MAR proteins (68, 72, 73, 74) important for virus replication and 
neurovirulence. MDs of alphaviruses hydrolyze the ester bonds between ribose and 
negatively charged amino acids (78). Mutations in the two functional loops of the 
alphavirus MD resulted in less virus replication in neuronal cells and decreased 
neurovirulence in mice (72, 73, 74, 75). 
 Earlier studies determined the roles in viral replication of the ADPr-binding and 
hydrolase activities of the alphavirus nsP3 MD (nsP3MD) in neuronal cells. ADP 
ribosylation of proteins and nsP3MD ADPr binding are necessary for initiation of alphavirus 
 29 
replication, while hydrolase activity facilitates amplification of replication complexes (73). 
Both activities were also important determinants of the outcome and pathogenesis of 
alphavirus encephalomyelitis in mice. Compared to the WT, the virus mutant with 
decreased hydrolase and binding activities replicated less well in both the brain and spinal 
cord, induced similar innate responses, and caused less severe disease with full recovery 
of survivors, whereas the virus mutant with better binding activity, but less hydrolase 
activity replicated well, induced higher expression of interferon-stimulated and NF-kB-
induced genes, and was cleared more slowly from the spinal cord with persistent paralysis 
in survivors (74). 
While recent studies mainly focused on murine neuronal cells in vitro and 
demonstrated a role in the pathogenesis of alphavirus encephalomyelitis in mice (72,73), 
in the present study we seek to determine the role of ADPr-binding and hydrolase 
activities of alphavirus nsP3MD in viral replication in astrocytes, the preferred target cells 











2.2 Materials and Methods 
Cell Culture  
Murine astrocytic C8-D1A (astrocyte type I clone), baby hamster kidney 21 (BHK 
21), and African green monkey epithelial (Vero) cells from American Type Culture 
Collection (ATCC) were cultured at 37oC and 5% CO2 in Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Atlanta Biologicals), L-glutamine (2mM; Gibco), streptomycin (100ug/mL; Gibco), 
and penicillin (100 U/mL; Gibco).  
Viruses, Mutagenesis, and Infection 
A full-length cDNA clone of 181/25 (CHIKV vaccine strain, a kind gift from Naomi 
Forrester, UT Medical Branch at Galveston, TX) was used to transcribe viral RNA using 
mMESSAGE mMACHINE SP6 Kit (Invitrogen). Viral RNA was transfected into BHK21 
cells using Lipofectamine 2000 (Invitrogen) to rescue virus (89). Point mutations in the 
nsP3 gene were introduced into the 181/25 cDNA clone using the Quikchange Site-
Directed Mutagenesis kit to create two viable nsP3MD mutant viruses, G32S and Y114A 
(72). Virus stocks were grown in BHK-21 cells, and viral RNAs from stock virus were 
sequenced to confirm the mutation within the nsP3 gene. Virus titers were determined by 
plaque assay in Vero cells. C8-D1A cells were infected at the indicated multiplicity of 
infection (MOI) with CHIKV 181/25 (WT) and nsP3MD mutants, G32S and Y114A. Cell 
viability was determined by trypan blue exclusion and reported as percent of day 0 cells. 
Infectious Virus Titers by Plaque Assay 
90% confluent 6-well plates of Vero cells were used for plaque assays. 10 fold 
dilutions of samples were made and 200 µL were added to each well and incubated at 
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37oC and 5% CO2 for one hour with gentle shaking every 15 minutes. After an hour, each 
well was overlaid with 1.5 ml of 0.6% Bacto agar (BD) in modified Eagle medium (MEM; 
Gibco) The plates were incubated at 37oC, 5% CO2 for 48 hours. The cells were then 
fixed with 10% formaldehyde in PBS and stained with 0.02% crystal violet for 30 minutes, 
and plaques were counted. 
Infectious Center Assay with RNA and Virus 
C8-D1A cells were infected with WT or nsP3MD mutants at MOIs of 0.5 and 5 and 
incubated for 1 hour at 4oC and transferred to 37oC for 4h or were transfected with 10 µg 
of RNA from a full-length clone of CHIKV 181/25 (WT) or nsP3MD mutants using the 
Amaxa nucleofector (73). Transfected and infected C8-D1A cells were trypsinized, and 
serial 10-fold dilutions of cells were plated on 90% confluent BHK-21 cells (for transfected 
cells) or Vero cells (for infected cells). After the addition of infected or transfected C8-D1A 
cells, cells were overlaid with 1.5ml of 0.6% Bacto agar in MEM. Plates were incubated 
for 48 hours at 37oC incubator and then were fixed with 10% formaldehyde in PBS and 
stained with 0.02% crystal violet, and plaques were counted.  
Flow Cytometry for dsRNA staining 
C8-D1A cells were infected with WT or nsP3MD mutants, G32S and Y114A at an 
MOI of 5 or mock-infected and incubated at 37oC for the designated amounts of time. The 
cells were trypsinized followed by live/dead staining (Invitrogen) for 30 mins on ice in the 
dark. Cells were then fixed with 2% formaldehyde in PBS for 30 mins and were 
permeabilized with 0.2% Triton in FACS buffer (PBS with 0.4% 0.5mM EDTA and 0.5% 
BSA) for 30 minutes in ice. Cells were stained for dsRNA with J2 mouse monoclonal 
antibody (Mab) (1:1000 dilution; Scicons) and incubated for an hour on ice (73) followed 
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by secondary PE-conjugated anti-mouse IgG antibody (1:400 dilution) for 45 mins (73). 
Cells were analyzed on a FACS Canto flow cytometer (Becton-Dickinson). Histograms 
were plotted and percent of live cells positive for dsRNA was quantitated.  
qRT PCR for PARP Gene Expression 
C8-D1A cells either mock-infected or infected with CHIKV WT at MOI of 5 were 
harvested using the RLT buffer (Qiagen), and RNA was isolated using RNeasy Mini kit 
(Qiagen). cDNA was synthesized from RNA using the High Capacity cDNA reverse 
transcription kit (Life Technologies), and Parp1, Parp9, Parp10, Parp12, Parp13, and 
Parp14 mRNAs were measured through qRT-PCR using TaqMan gene expression 
assays. Relative gene expression was determined using the ΔΔCT method using 0-hour 
control samples, and Gapdh for normalizing the PARP expression. Under the following 
conditions with 40 cycles: 2 minutes of 50oC, 10 minutes of 95oC, and 1 min of 60oC, PCR 
was performed in Applied Biosystems 7500 Real-time PCR machine (73). 
qRT PCR for Viral RNA Synthesis 
RNeasy Plus mini kit (Qiagen) was used to isolate total RNA from C8-D1A cells 
infected with CHIKV 181/25 or nsP3MD mutants, G32S and Y114A at an MOI of 5. cDNA 
was synthesized from RNA using the High Capacity cDNA reverse transcription kit (Life 
Technologies) (73). qRT-PCR was performed using TaqMan primers and probes specific 
for the genomic (nsP2) and genomic plus sub-genomic (E2) regions of the CHIKV 
genome: for the CHIKV E2 gene: E2 922F 5′-GAAGAGTGGGTGACGCATAAG-3′; E2 
1011R 5′-TGGATAACTGCGGCCAATAC-3′); for the TaqMan probe: CHK E2 949 5′-6-
carboxyfluorescein [FAM]-ATCAGGTTAACCGTGCCGACTGAA-Minor groove binder 
(MGB) nonfluorescent quencher (NFQ)-3′ (Applied Biosystems); for the CHIKV nsP2 
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gene: nsP2 1247F 5′-GTACGGAAGGTAAACTGGTATGG-3′; nsP2 1359R 5′-
TCCACCTCCCACTCCTTAAT-3′); and for the TaqMan probe: CHIKV nsP2 1304 5′-
(FAM)-TGCAGAACCCACCGAAAGGAAACT-(MGB NFQ)-3′ (Applied Biosystems) (73). 
Copies of viral RNA were quantified using a standard curve constructed from 10-fold 
dilutions of a pCRII-TOPO plasmid containing the CHIKV E2 or nsP2 region cDNA and 
normalized to endogenous rodent Gapdh. Data are plotted as mean CHIKV RNA copies 
per 106 copies of Gapdh (73). 
Western Blot Analysis of ADP Ribosylation and Protein Expression 
C8-D1A cells were infected with WT or nsP3MD mutants, G32S and Y114A at an 
MOI of 5 or mock-infected and incubated at 37oC for different time points. At each time 
point, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris (pH 
8), 1 % Triton X-100, 0.1 % of SDS, 150 mM NaCl, 1 mM EDTA, and 0.5 % Na3VO42H2O) 
supplemented with protease and phosphatase inhibitors (Sigma) (73). The lysates for 
ADP-ribosylated protein analyses were collected in RIPA buffer supplemented with PARP 
inhibitor (Sigma) and PARP glycohydrolase inhibitor (Millipore) in addition to protease and 
phosphatase inhibitors. The lysates were incubated in ice for 30 minutes followed by 
centrifugation at 15,200 x g for 10 min to collect supernatant proteins. Dc protein assay 
(Bio-Rad) was performed to estimate total protein levels of lysates with BSA as the 
standard. 15 µg of proteins were loaded to 10% polyacrylamide gels, separated via 
electrophoresis, and transferred to nitrocellulose membranes. Membranes were blocked 
with 5% skim milk in PBS followed by incubating overnight at 4oC with polyclonal rabbit 
antibodies to CHIKV nsP1, nsP2, nsP3 (1:10000) (73,90), mouse Mab E2 structural 
proteins (1:1000) (CHK-187 11A4. F1.F4) (53), phosphor-eIF2a, eIF2a (1:1000; Cell 
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Signaling Technologies (CST)), pan ADPr-binding reagent (1:1000; Millipore), or β actin 
(1:5000; Millipore) diluted in 5% BSA in tris-buffered saline and Tween 20 (TBST). 
Secondary antibodies were HRP-conjugated either anti-mouse or anti-rabbit antibodies 
(1:1000; Cell Signaling Technologies) diluted in 2% milk and incubated for an hour at RT. 
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) was used to 
develop the membrane. ImageJ software from NIH was performed to analyze the 
densitometry of immunoblots from three to five independent experiments. 
Puromycin translation assay 
C8-D1A cells were infected with WT or nsP3MD mutants, G32S and Y114A at an 
MOI of 5 or mock-infected and incubated at 37oC for different time points. After an hour 
of infection, fresh DMEM with 1% FBS was substituted. At particular time points, the 
media from the wells were removed, and DMEM containing 5 µg/mL puromycin 
dihydrochloride (Sigma) was added and incubated for 10 minutes. The cells were then 
collected in RIPA buffer and immunoblotted using mouse anti-puromycin Mab clone 
12D10 (1:1000; Millipore) (73). Membranes were incubated in secondary antibody HRP-
conjugated anti-mouse IgG (1:10000; CST) and developed using Amersham ECL Prime 
Western Blotting Detection Reagent. ImageJ software from NIH was performed to 
analyze the densitometry of immunoblots from three independent experiments. 
H2O2 Treatment 
C8-D1A cells were mock-treated or treated with 2ml of DMEM containing 4 µl of 
H2O2 (3 or 30%). After 15 mins of incubation, treated C8-D1A cells were washed once 
with PBS and collected in RIPA buffer for immunoblotting using pan ADPr-binding reagent 
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(1:1000; Millipore), followed by HRP-conjugated anti-rabbit IgG. The membrane was 
developed using the Amersham ECL Prime Western Blotting Detection Reagent. 
35S Pulse Chase Analysis of E2 Viral Protein Processing  
C8-D1A cells were infected with WT or nsP3MD mutants, G32S and Y114A at an 
MOI of 5 and incubated at 37oC for different time points. At 12- and 24-hour after infection, 
cells were washed with PBS followed by incubation in DMEM media without methionine 
(Met) and cysteine (Cys) (Gibco) for an hour. The cells were then pulsed with Met/Cys-
free DMEM containing 35S (100µCi/ml) for 30 minutes at 37oC, 5% CO2. To chase the 
labeled proteins, cells were washed and incubated with media having 15mg/L of L-
methionine for 0, 40, and 90 minutes. The supernatant fluids were collected in a 15ml 
conical tube and the cell lysates were collected in RIPA buffer containing phosphatase 
and protease inhibitors.  
For immunoprecipitation, the DC assay was used to estimate protein amounts. 300 
to 400 µg of total protein were incubated with 10 µg of mouse anti-E2 Mab at 4oC 
overnight with gentle rocking. 40 µl of prewashed ImmunoPure Immobilized Protein A/G 
(Pierce) beads were added to the mixture of cell lysate and E2 antibody, followed by 
overnight incubation at 4oC with gentle rocking. Beads were washed four times with RIPA 
buffer, and bound proteins were eluted by boiling with SDS loading buffer.  
For supernatant fluids, 1/4th volume of polyethylene glycol solution (PEG 8000 and 
NaCl, pH 7.2) was added to the supernatant and incubated overnight at 4oC. 
Supernatants were centrifuged at 13,500 x g for 30 minutes to pellet the PEG precipitated 
virions. The pellet was boiled in SDS loading buffer. Eluted lysates and PEG-precipitated 
virions from supernatant samples were loaded onto 10% polyacrylamide gels and 
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electrophoresed. Gels were fixed with the fixing solution (10% acetic acid and 20% 
methanol) for 30 minutes and washed with water for an hour with water replacement every 
15 minutes. Gels were enhanced with 1M sodium salicylate (Sigma) solution (pH 5 to 7) 
for 30 minutes and dried using a dryer at 56oC until the gel is dried. The radioactive gel 
was exposed to ECL X-ray (GE Healthcare) film until signals were detected. 
IFNa and IFN β Enzyme ELISA 
Supernatants of C8-D1A cells either mock-infected or infected with CHIKV 181/25 
or nsP3MD mutants, G32S and Y114A at an MOI of 5 were collected at different time 
points. The levels of IFNa and IFNβ were measured using VeriKine ELISA kits (PBL 
Assay Science) according to the manufacturer’s instructions (73). Assay ranges were 
12.5-500 pg/mL for IFNa and 15.6-1000 pg/mL for IFN β. 
In vitro IFN blockade 
C8-D1A cells were infected with WT or nsP3MD mutants, G32S and Y114A at an 
MOI of 5 and incubated at 37oC in DMEM 1%FBS containing antibodies against IFNa 
alone or IFNβ alone or IFNa and β together or the Pan isotype control at concentrations 
of 10µg, 5µg, 1µg or nil (Leinco Technologies) and incubated for 8 or 24 hours. The cells 
were collected in RIPA buffer containing protease and phosphatase inhibitors and 
immunoblotted for phospho-STAT1 (1:500; CST), STAT1 (1:1000; CST), or β actin to 
observe STAT1 activation. Secondary anti rabbit or anti mouse antibodies were used, 
and the membrane was developed using Amersham ECL Prime Western Blotting 
Detection Reagent.  
After optimizing the concentration of antibody for blocking IFN activity C8-D1A cells 
were infected with CHIKV WT and Y114A at an MOI of 5 and with G32S at an MOI of 0.5 
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and incubated at 37oC in DMEM 1%FBS with antibodies against IFNa and β together at 
concentrations of 10µg, 1µg or nil for different times.  Supernatant was collected at each 
time point, and plaque assays were performed to measure the viral production.  
Statistical Analysis 
Prism 8 (GraphPad) was used for two-way ANOVA tests to calculate significant 
differences between different infections at a single time point. All results were shown as 



















CHIKV with nsP3MD Mutations That Affect ADPr- Binding and Hydrolase Activities 
Replicate Less Efficiently in Astrocytic Cells. 
To determine the role of ADPr binding and hydrolase activities in viral replication 
in astrocytes, C8-D1A cells were infected with CHIKV 181/25 (WT) and nsP3MD mutants 
G32S (decreased hydrolase and binding activities) and Y114A (decreased hydrolase and 
increased binding activities) at an MOI 5 (72,73). Virus production was quantitated by 
plaque formation in Vero cells (Fig. 2.1B), and cell viability was determined by trypan blue 
exclusion (Fig. 2.1A) WT and Y114A replicated with similar kinetics and at 24hpi Y114A 
had more viable cells (P<0.05 vs WT) and higher viral titer than WT (P<0.01 vs WT). The 
G32S virus replicated less well than WT and Y114A from 6hpi onwards (P<0.0001 vs WT, 
P<0.05 vs Y114A, 6hpi) except 24hpi and was also lower at 36hpi (P<0.0001v 
WT/Y114A). The cell numbers at 36hpi in all three infected groups were similar. 
nsP3MD Mutations That Affect ADPr-Binding and Hydrolase Activities Affect the 
Formation of Functional Replication Complexes in Astrocytes.  
The formation of functional replication complexes to amplify genomic viral RNA is 
determined by how successfully the replication complexes are established. To determine 
whether the activities of nsP3MD affect the initiation of infection, infectious center assays 
were performed both by electroporating the same amount of RNA (Fig. 2.2A) and by 
infecting with virus at an MOI of 0.5 and 5 (Fig. 2.2B). RNA transcribed from WT and two 
nsP3MD cDNA clones was electroporated into C8-D1A cells, co-cultured with BHK-21 cells 
and plaque formation assessed. G32S transfected C8-D1A cells produced fewer 
infectious centers than WT (P < 0.0001) and Y114A (P < 0.01). Y114A RNA transfected 
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C8-D1A cells also produced fewer infectious centers than WT (P < 0.001). Similar results 
were obtained when the infectious center assay was performed by exposing the cells to 
virus and mutants at the MOIs of 5 and 0.5. G32S mutant successfully infected fewer C8-
D1A cells than WT at both MOIs (1267 G32S vs. 2592 WT infectious centers per 3x105 
at an MOI of 0.5, P <0.0001); (67667 G32S vs. 162500 WT infectious centers per 3x105 
cells at an MOI of 5, P <0.0001). However, Y114A mutant produced numbers of infectious 
centers similar to WT and more than G32S (1267 G32S vs. 2742 Y114A infectious 
centers per 3x105 cells at an MOI of 0.5, P <0.0001); (67667 G32S vs. 145000 Y114A 
infectious centers per 3x105 at an MOI of 5, P <0.0001). Therefore, ADPr-binding activity 
is more important than hydrolase activity for establishing infection. 
 After replication complexes are established, they are amplified with increasing 
numbers of spherules with dsRNA producing negative-strand template genomic RNA and 
positive strand genomic and subgenomic RNA. To assess amplification of replication 
complexes, C8-D1A cells were infected with WT and nsP3MD mutants at an MOI of 5, 
stained with antibody to dsRNA and analyzed by flow cytometry (Fig. 2.3). At 4 and 6hpi, 
C8-D1A cells infected with WT and mutants did not show any difference in the number of 
dsRNA positive cells. However, at 8 and 12hpi, more C8-D1A cells infected with Y114A 
were positive for dsRNA than cells infected with WT and G32S (Fig. 2.3A and Fig. 2.3B). 
Individual C8-D1A cells infected with WT amplified more replication complexes than cells 
infected with G32S throughout the infection and cells infected with Y114A until 12hpi by 
comparing the fluorescent intensities (Figure 2.3C). Therefore, the nsP3MD mutant virus 
with impaired ADP ribosyl hydrolase and binding activities made lesser replication 
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complexes compared to WT, while the mutant with better ADP ribosyl binding activity 
made replication complexes better or similar as compared to WT. 
CHIKV Infection of C8-D1A Cells Induced increased PARP Gene Expression, But 
Not ADP-Ribosylation of Proteins.  
In neuronal cells CHIKV infection leads to activation, but not increased PARP gene 
expression with increased ADP ribosylation of proteins. To determine whether there is 
modulation of PARP expression, C8-D1A cells were infected with CHIKV WT at an MOI 
of 5 and mRNAs quantified by qRT-PCR.  PARPs known to be induced by IFN (PARP 9, 
10, 12, 13 and 14) were induced with a peak at 6hpi (P<0.0001) and sustained until 24hpi 
(Fig. 2.4A). 
To determine whether CHIKV infection leads to ADP-ribosylation of proteins, 
lysates of C8-D1A cells infected with WT and nsP3MD mutants were analyzed by 
immunoblot using an ADPr binding reagent that detects both MARs and PARs as well as 
antibody to the E2 glycoprotein (Fig. 2.4B and Fig. 2.4C). There was no or little ADP-
ribosylation of proteins in CHIKV infected C8-D1A cells compared to mock-infected cells. 
Infection was confirmed by E2 protein expression (Fig. 2.4B). However, C8-D1A cells 
under oxidative stress after exposure to H2O2-containing media, induced ADP-
ribosylation of proteins (Fig. 2.4D).  
Viral RNA and Protein Synthesis and Processing in Infected Astrocytes  
After spherules are formed for replication complexes at the plasma membrane, 
genomic and subgenomic RNAs are amplified within the infected cells. To assess viral 
RNA synthesis WT and nsP3MD mutant infected cells, RNA was quantified by RT-qPCR 
(Fig. 2.5). Genomic viral RNA (Fig. 2.5B) made by the mutant with impaired ADP ribosyl 
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binding and hydrolase activity (G32S) is less throughout infection while subgenomic RNA 
(Fig. 2.5A) is less only early. The levels of Y114A mutant genomic and subgenomic RNA 
were similar to WT. 
 Nonstructural proteins translated from genomic RNA amplify replication complex 
formation. To determine how nsP3MD mutation affects the translation of nsPs, C8-D1A 
cell lysates infected with CHIKV WT or nsP3MD mutants at an MOI of 5 were 
immunoblotted to detect nsP synthesis (Fig. 2.6A). The G32S mutant produced less nsP 
early but reached levels of nsPs similar to WT and Y114A by 8hpi (Fig. 2.6B). As predicted 
by the dsRNA staining (Fig 2.3), Y114A mutant had greater nsP production throughout 
infection compared to WT and G32S. The increased binding ability of Y114A was 
associated with formation of more dsRNA-positive cells, more translation of nsPs and 
more genomic RNA.  
Later stable replication complexes transcribe sgRNA for translation of structural 
proteins. To determine the synthesis of structural proteins, the lysates were 
immunoblotted to assess E2 glycoprotein production (Fig. 2.4A). Surprisingly, more E2 
glycoprotein was made by cells infected with the G32S mutant than cells infected with 
WT and Y114A, especially at 24hpi (P<0.001 vs WT, P<0.01vs Y114A) and 36 hpi 
(P<0.01 vs WT) (Fig. 2.7A). Y114A mutant produced slightly more E2 protein than WT at 
36hpi.  
To determine whether the ADPr hydrolase and binding activities of nsP3MD affects 
processing of the structural polyprotein in astrocytes was analyzed through a pulse-chase 
experiment. Infected cells were labeled for 30 min at 12 and 24h after infection, chased 
for the indicated times, and the E2 glycoprotein immunoprecipitated (Fig. 2.7B).  At 12hpi 
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WT infected cells synthesized more pE2 than Y114A- infected cells, which produced more 
than G32S-infected cells. However, at 24hpi, the cells infected with nsP3MD mutants 
G32S and Y114A had more pE2 than WT. However, the rate of synthesis was the same 
in all the three viruses. Virions released with labeled E2 were similar in amount at 12hpi 
whereas at 24hpi the nsP3MD mutants especially G32S had more released E2. Therefore, 
mutant-infected cells produced more structural proteins and these proteins were 
processed normally. 
Type I IFN Does Not Affect Virus Replication of nsP3MD Mutants.  
To determine the host response to virus infection, supernatants of C8-D1A cells 
infected with WT or nsP3MD mutants were tested for type I IFN production by ELISA (Fig. 
2.8). Y114A induced more astrocyte production of IFNβ than WT (P<0.0001 6hpi; 
P<0.001 12hpi) and G32S (P<0.0001) at early time points. Later in infection both nsP3MD 
mutants induced more IFNα (P<0.05) and IFNβ (P<0.001 G32S; P<0.01 Y114A) than WT 
(Fig. 2.8A and Fig. 2.8B).  
To determine whether type I IFN production actually improves WT or nsP3MD 
mutant virus replication, IFNα and IFNβ neutralizing antibodies were added to the cultures 
(Fig. 2.9 and Fig. 2.10). To optimize the concentration of antibodies for blocking IFNα and 
IFNβ signaling in C8-D1A cells, CHIKV-infected C8-D1A cells were mock treated or 
treated with antibodies against IFNα, IFNβ alone or in combination, or treated with isotype 
antibody at concentrations of 10µg, 5µg, and 1µg per ml. Activation of STAT1  was 
assessed by immunoblotting lysates for pSTAT1 (Fig 2.9). Although neither IFNα nor 
IFNβ antibodies alone completely inhibited the activation of STAT1, IFNα and IFNβ 
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antibodies in combination (10µg) blocked phosphorylation of STAT1 at 8 and 24hpi after 
infection (Fig. 2.9C and Fig. 2.9F).  
The effect of blocking the type I IFN signaling on viral replication in C8-D1A cells 
infected with WT and Y114A at MOI of 5, and G32S infected cells at MOI of 0.5 was 
assessed by plaque assay (Fig. 2.10). There were no significant differences in virus 
production between antibody-treated and isotype-treated cells for WT and Y114A. 
Blocking by type I IFN antibody improved G32S replication compared to isotype treatment 
at an early time point (Fig. 2.10D, Fig. 2.10E, and Fig. 2.10F). While more type I IFN was 
produced upon the infection by nsP3MD mutants, it had little effect on virus replication. 
Impaired nsP3MD ADP Ribosyl Binding and Hydrolase Activity Results in Decreased 
Host Translational Shutoff. 
Alphaviruses induce host translational shutoff in part by activating PKR to 
phosphorylate translational initiation factor eIF2a to facilitate translation of viral structural 
proteins from subgenomic RNA. We evaluated the effect of nsP3MD mutations on host 
protein synthesis in astrocytes by immunoblotting for phospho eIF2α (Fig. 2.11A and Fig. 
2.11B) and by assessing overall protein synthesis by incorporation of puromycin, a 
structural analog of aminoacyl tRNA, into newly synthesized proteins (Fig. 2.11C and Fig. 
2.11D). Phosphorylation of eIF2α occurs very early (4hpi) in astrocytes as nsPs are 
translated and RNA is synthesized. At 6hpi, the ratio of phosphorylated eIF2α relative to 
total eIF2α was higher in WT-infected cells compared to G32S and Y114A-infected cells 
(P<0.05). At 24 hpi, however, Y114A had a higher p-eIF2α: eIF2a ratio than WT (P<0.01) 
or G32S (P<0.001). G32S had lower levels of p-eIF2α throughout infection. The 
puromycin translational assay did not show any difference between WT and nsP3MD 
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mutants until 24hpi. At 36hpi, there was less translational shut off in G32S-infected 



















Figure 2.1 Astrocyte Cell Viability and Infectious Virus Production after Infection 
with CHIKV WT and nsP3MD Mutants. C8-D1A cells were infected with 181/25 (WT) or 
two nsP3MD mutants at an MOI of 5. (A) Cell viability was measured by trypan blue 
exclusion at four time points after infection. (B) Supernatant fluids were collected, serially 
diluted and plated on Vero cells for the plaque formation. The data represent the mean ± 
SD from two independent experiments performed in triplicate. ⋆⋆ P < 0.01, ⋆⋆⋆ P < 0.001, 
⋆⋆⋆⋆ P < 0.0001 (WT vs. G32S); # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001 
(G32S vs. Y114); ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 (WT vs. Y114A). 
 
 
Figure 2.2: Establishment of Infection in Astrocytes by Transfected Viral RNA and 
Infectious Virus from WT and nsP3MD mutants. (A) 10 µg RNA of 181/25 (WT) or two 
nsP3MD viral were electroporated into 105 C8-D1A cells that were serially diluted and 
plated on confluent BHK21 cells, overlaid with agar and plaques produced by virus-
infected cells counted. (B) C8-D1A cells were infected with WT or two nsP3MD mutants at 
MOIs of 0.5 and 5, incubated an hour at 40C and 370C for 4 hours. Cells were trypsinized, 
serially diluted, plated on Vero cells, overlaid with agar and plaque formation assessed.  
The data indicate the mean ± SD from two independent experiments done in triplicate. 
⋆⋆⋆⋆ P < 0.0001 (WT vs. G32S); ## P < 0.01, #### P < 0.0001 (G32S vs. Y114); ^^^ P < 





Figure 2.3 Formation and Amplification of Replication Complexes in Astrocytes 
Infected with WT and nsP3MD Mutants. C8-D1A cells infected with 181/25 (WT) virus 
or nsP3MD mutants at an MOI of 5. Cells were live/dead stained, fixed, permeabilized, and 
stained for dsRNA with J2 MAb and analyzed by flow cytometry. (A) Histograms of 
representative data from three independent experiments done in triplicates. Yellow line 
indicates uninfected cells. (B) The percent of dsRNA positive live cells was quantified. (C) 
The median fluorescent intensities were measured. The data present the mean ± SD from 
three independent experiments. ⋆⋆⋆ P < 0.001, ⋆⋆⋆⋆ P < 0.0001 (WT vs. G32S); ### P 












Figure 2.4 PARP mRNA Expression and ADP Ribosylation of Proteins During 
CHIKV WT and nsP3MD Mutants Infection in Astrocytes. (A) C8-D1A cells infected with 
WT at an MOI of 5, and six different PARPs mRNAs were quantified by qRT-PCR. PARP 
mRNA change is indicated as the average ± SD from three independent experiments. ⋆ 
P < 0.05, ⋆⋆ P < 0.01, ⋆⋆⋆⋆ P < 0.0001 (WT vs. Mock). (B) Lysates from C8-D1A cells 
infected with CHIKV 181/25 (WT) or two nsP3MD mutants at an MOI of 5 were 
immunoblotted for ADPr and the E2 structural protein. β-actin was the loading control. A 
representative blot from three independent experiments is shown. (C) Quantification of 
ADPr was measured and normalized to actin level by densitometry from three 
independent experiments.  (D) C8-D1A cell lysates treated with H2O2 and mock-treated 
lysates immunoblotted for ADPr. A representative blot from three independent 







Figure 2.5 Levels of Genomic and Genomic Plus Subgenomic Viral RNA produced 
by Astrocytes infected with CHIKV WT and nsP3MD Mutants. (A) Genomic and (B) 
genomic plus subgenomic RNA produced in C8-D1A cells infected with 181/25 (WT) virus 
or nsP3MD mutants at an MOI of 5 were quantified by qRT-PCR. The mean ± SD from 
three independent experiments are plotted. ⋆ P < 0.05, ⋆⋆⋆ P < 0.001, ⋆⋆⋆⋆ P < 0.0001 







Figure 2.6 nsP Translation upon Infection by CHIKV WT and nsP3MD Mutants in 
Astrocytes. Lysates from C8-D1A cells infected with CHIKV 181/25 (WT) or nsP3MD 
mutants at an MOI of 5 were immunoblotted with antibodies against nsP1, nsP2, nsP3 
and β-actin. (A) A representative image from five independent experiments. (B) Levels of 
nsPs measured by densitometry and normalized to actin levels graphed from five 
independent experiments. Data illustrate the mean ± SD. # P < 0.05, ### P < 0.001 (G32S 







Figure 2.7 Effects of nsP3MD Mutation on Viral Structural Protein Synthesis and 
Processing in Astrocytes. (A) Lysates from C8-D1A cells infected with CHIKV 181/25 
(WT) or nsP3MD mutants at an MOI of 5 were immunoblotted with antibodies to the E2 
structural protein and β-actin (Fig 2.4B). Levels of E2 were normalized to actin by 
densitometry from three independent experiments and data graphed as the mean ± SD. 
(B) Pulse-chase analysis of E2 processing in C8-D1A cells infected with WT or two 
mutants. Cells were pulsed with 35S-methionine at 12 and 24h and immunoprecipitated 
with antibody to E2. Virions were PEG precipitated from supernatant fluids. The samples 
were subjected to polyacrylamide gel electrophoresis, fixed, dried, exposed to X-ray film 
and developed. The figure is representative of four independent experiments. ⋆⋆ P < 0.01, 











Figure 2.8 Type I IFN Production after CHIKV WT and nsP3MD Mutants Infection of 
Astrocytes. (A and B) Amounts of type I IFN in supernatant fluids of C8-D1A cells 
infected with CHIKV 181/25 (WT) and nsP3MD mutants were measured by ELISA. Data 
show the mean ± SD from three independent experiments. ⋆ P < 0.05, ⋆⋆ P < 0.01, ⋆⋆⋆ P 
< 0.001 (WT vs. G32S); # P < 0.05, #### P < 0.0001 (G32S vs. Y114); ^ P < 0.05, ^^^ P 




Figure 2.9 Optimization of Antibody Concentrations Required for Blocking of type 
I IFN signaling in CHIKV-Infected C8-D1A Cells. (A to F) C8-D1A cells uninfected or 
infected with 181/25 (WT) virus at an MOI of 5 and mock treated or treated with antibodies 
against IFNα, IFNβ, or IFNa plus IFNb, or treated with isotype antibody at 10µg, 5µg, and 
1µg/ml. Lysates were immunoblotted with antibodies against phospho STAT 1, STAT 1, 
and β-actin at 8 and 24hpi.  
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Figure 2.10 Infectious Virus Produced by CHIKV WT and nsP3MD Mutants upon Type 
I IFN Blocking in Astrocytes. C8-D1A cells were infected with WT and Y114A at MOI 
of 5 and G32S at MOI of 0.5 and treated with either 10µg or 1µg of type I IFN blocking or 
isotype control antibodies. Serially diluted culture fluids were assessed for plaque 
formation on Vero cells. (A-C) WT replication in the presence of control and IFNa plus 
IFNb antibody at 1 (A,C) and 10 (A, C) ug/ml. (D-F) G32S replication in the presence of 
control and IFNa plus IFNb antibody at 1 (D,F) and 10 (D,E) ug/ml. (G-I) Y114A replication 
in the presence of control and IFNa plus IFNb antibody at 1 (G,I) and 10 (G,H) ug/ml. 
Data are presented as mean ± SD from three independent experiments. ⋆ P < 0.05, ⋆⋆ P 










Figure 2.11 Host Translational Shut off in Astrocytes Infected with CHIKV WT and 
nsP3MD Mutants. C8-D1A cells were infected with CHIKV 181/25 (WT) or nsP3MD 
mutants at an MOI of 5 (A, B) Lysates were immunoblotted for phosphorylated eIF2ɑ, 
total eIF2ɑ, and β actin. (A) A representative blot from four different experiments. (B) The 
ratio of phosphorylated eIF2ɑ to total eIF2ɑ determined by densitometry and normalized 
to β actin. Data are plotted as the mean fold change relative to mock-infected C8-D1A 
cells ± SD. (C, D) Lysates from infected C8-D1A cells incubated with medium containing 
puromycin were immunoblotted with antibodies to puromycin and β actin. (C) 
Representative image from three independent experiments. (D) Puromycin staining 
normalized to β actin plotted as mean fold change relative to mock-infected C8-D1A cells 
± SD. ⋆ P < 0.05, ⋆⋆⋆ P < 0.001 (WT vs. G32S); # P < 0.05, ## P < 0.01, ### P < 0.001 












 Recent outbreaks of the reemerging Old-World alphavirus CHIKV demonstrate 
unusual neurovirulence among patients. When CHIKV crosses the blood brain barrier and 
cerebrospinal fluid, infection of CNS cells, such as neurons, astrocytes, and microglial 
cells can occur (26). Death of CNS cells induced by viral infection can lead to long-term 
neurological sequelae in patients when cells cannot be replaced (26). Alphavirus nsP3 
influences virus replication in the brain and is an important determinant of neurovirulence 
(68, 72, 73, 74). The macrodomain of nsP3 has mono ADPr binding and hydrolase 
activities that affect formation of replication complexes and synthesis of viral RNA (72, 
73). Mutations introduced into either the catalytic loop related to hydrolase activity or the 
pyrophosphate loop related to binding activity of the active site, attenuated neurovirulence 
for mice (73, 74, 75). Our previous studies to assess the role of the MD in viral replication 
analyzed neuronal infection, In this study, we analyzed infection of astrocytes, the most 
frequent target for CHIKV of the CNS. 
 The alphavirus virus replication cycle begins with translation of the nonstructural 
proteins, establishment and amplification of replication complexes for the synthesis of 
genomic and subgenomic RNA (Fig. 2.5), translation of viral structural proteins (Fig. 2.4 
and Fig. 2.6), and production of infectious virus (Fig 2.1B). Virus with an nsP3MD mutation 
that decreased binding and hydrolase activities (G32S) was inefficient at initiation of 
infection and formation of functional replication complexes (Fig. 2.2 and Fig. 2.3) 
compared to WT. G32S produced less genomic and subgenomic RNA, less nsP 
synthesis, and infectious virus with limited host translational shut off in infected 
astrocytes. 
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When binding activity is increased but hydrolase activity is decreased in nsP3MD 
mutant Y114A, the initiation of infection and formation of replication complexes were were 
not compromised at earlier time points and at later time points, Y114A produced more 
replication complexes, although genomic and subgenomic RNA, nsP synthesis, and 
infectious virus were similar to WT. Similar to what we observed in neuronal cells, 
increased ADPr binding activities partially compensated for decreased hydrolase activitiy 
and made the mutants produce more RNA, more nsP translation, and eventually the virus 
production. Thus, nsP3MD binding and hydrolase activities are important in the virus 
replication cycle in astrocytes as well as neurons.  
 However, differences in the cellular responses were observed. C8-D1A cells 
produced type I IFN (Fig. 2.8), and upregulated the expression of IFN-stimulated PARP 
gene expression upon infection while neuronal cell did not (Fig. 2.4D). However, blocking 
IFN signaling with antibodies to both IFNa and IFNb did not alter virus replication (Fig. 
2.9). Despite increased PARP gene expression, infection of astrocytic cells did not 
increase ADP ribosylation of proteins as was seen with neuronal cells. The results may 
be explained by production of more infectious virus after the first round of replication in 
astrocytes. Infected astrocytes produced 3 to 100 times more CHIKV than infected 
neurons (53 and Fig. 2.1B) and hydrolase activity of nsP3 might remove ADPribose 
moiety from MARylated substrates, with increased expression of PARPs. 
 Importantly, the defect in production of structural proteins associated with nsP3MD 
mutants in neurons was not observed in astrocytes. NSC34 neuronal cells infected with 
nsP3MD mutants showed defects in structural protein synthesis compared to WT. In 
contrast, astrocytes infected with nsP3MD mutants produced more structural proteins than 
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WT (Fig. 2.7) and had similar processing rates (Fig. 2.7B). The reason for this is currently 
























Understanding the signaling pathways leading to the type I interferon 
production by astrocytes, but not neurons. 
3.1 Introduction 
 Both the innate and adaptive immune systems are essential to protect the host 
from pathogens (51). The innate immune system is the frontline of the battle by enabling 
the host to sense the existence of the pathogen, inhibiting replication, and alerting the 
adaptive immune response for activation (47). Pattern Recognition Receptors (PRRs) 
recognize specific pathogen-associated molecular patterns and send signals to activate 
proteins and induce gene expression. The upregulation of antiviral genes induces 
production of antiviral proteins, inflammatory chemokines and cytokines to counter the 
pathogen. Natural Killer (NK) cells induce cytolysis of infected cells to eliminate existing 
pathogens (57). Dendritic cells and other antigen-presenting cells process the antigens 
and express the epitopes on MHC class I molecules and MHC Class II molecules to 
activate adaptive immune cells such as B cells and T cells. 
The adaptive immune system can recognize processed foreign antigens, develop 
the response against specific antigens of the pathogens, and establish memory of the 
antigens to combat future infection (49). While MHC Class I molecules are expressed by 
all nucleated cells of vertebrates, MHC Class II is found mainly on the surface of antigen-
presenting cells. B cells produce specific immunoglobulins against epitopes of viral 
proteins. Among the functions of antibodies are neutralization to block entry, opsonization 
to induce phagocytosis, and activation of complement. T cells trained through negative 
and positive selection against self-antigens in the thymus target virus-specific antigens 
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(49). Memory cells develop from active B cells and T cells in the lymph node to prepare 
against future infection. When a secondary infection happens, faster and stronger 
adaptive immune responses are triggered by memory cells. 
Cells identify viruses using TLRs, RLRs, and NLRs as their main pattern 
recognition receptors (PRRs) (50). After recognition of ssRNA and dsRNA or viral proteins 
by the receptors, they trigger phosphorylation of downstream signaling molecules to 
activate the type I IFN and NF𝛋B response pathways (50). TLRs and NLRs recognize 
ssRNA and activate the TRAF6 for phosphorylation of IKKβ and I𝛋B, releasing NF𝛋B to 
stimulate production of IL1β and TNFα that induce inflammation at sites of infection (50). 
TLR3 and RLRs activate the TRAF3 pathway to phosphorylate IRF3/7 and induce 
production of IFNa and IFNβ (48, 49). Type I IFN, cytokines, and interleukins can act 
through autocrine and paracrine signaling to activate the JAK/STAT pathway and 
upregulate expression of antiviral proteins. One ISG is the MHC class I molecule that 
presents processed viral peptides for presentation on the surface of infected cells. In 
addition, NK cells and inflammatory chemokines recruit and activate macrophages. NK 
cells also kill infected cells using perforin and secrete IFN𝛄 and TNFα to induce MHC 
Class II molecules (57). MHC Class II molecules present viral peptides that activate CD4+ 
T cells, and MHC Class I molecules present viral peptides that activate CD8+ T cells. 
CD4+ T cells produce diverse interleukins to regulate the adaptive immune response, and 
CD8+ T cells lyse virus-infected cells. B cells secrete specific antibodies with the help of 
CD4+ T cells. While cell-mediated innate and adaptive immune responses can clear the 
virus and cause neurological disease by destroying infected host cells, PRR-induced 
innate responses are important for detection early and induction of type I IFN (58).  
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Compared to neuronal cells, dsRNA staining of CHIKV infected astrocytes 
demonstrated production of more replication complexes faster. Astrocytes also produced 
more copies of viral RNA, higher levels of nsPs and more infectious virus compared to 
neurons indicating greater susceptibility of astrocytes to CHIKV infection. Upon CHIKV 
infection, type I IFNs were produced by astrocytes, but not by neurons. There was 
increased expression of IFN-stimulated PARPs upon alphavirus infection in CNS tissues 
of mice and in astrocytes, whereas in neuronal cells PARP activation without increased 
mRNA expression during virus infection resulted in ADP-ribosylation of proteins. The 
present study was pursued to better understand the innate immune pathways that 















3.2 Materials and Methods 
Cell Culture and IFN and Poly (I:C) Treatment 
The murine astrocytic C8-D1A (astrocyte type I clone) cell line from American 
Type Culture Collection, murine neuronal NSC34 cell line (from Neil Cashman, 
University of British Columbia) (91), and African green monkey epithelial (Vero) cells 
were cultured at 37oC and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Atlanta 
Biologicals), L-glutamine (2mM; Gibco), streptomycin (100μg/mL; Gibco), and penicillin 
(100U/mL; Gibco). To mimic dsRNA activation of innate responses during virus 
infection, C8-D1A and NSC34 cells were treated with low molecular weight (LMW) 
(1μg/ml) and high molecular weight (HMW) (1μg/ml; Invivogen)  poly (I:C), combined 
with transfection reagent, LyoVecTM in DMEM. For IFN stimulation, cells were treated 
with 2μl of IFNa A/D (100U/ml, PBL Bioscience) in DMEM for different amounts of time.  
Viruses and Infection 
A full-length cDNA clone of 181/25 (a kind gift from Naomi Forrester, UT Medical 
Branch at Galveston, TX) was used to transcribe viral RNA using mMESSAGE 
mMACHINE SP6 Kit (Invitrogen). For virus stocks BHK21 cells were transfected with 
viral RNA using Lipofectamine 2000 (Invitrogen) (89). Titers were determined by plaque 
assay in Vero cells. C8-D1A cells and NSC34 cells were infected at an MOI of 5 with 
CHIKV 181/25 (WT). Cell viability was measured by trypan blue exclusion and 
calculated as the percent of Day 0 cells. 
Infectious Virus Titers by Plaque Assay 
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90% confluent 6-well plates of Vero cells were used for plaque assays. 200 µL of 
serially 10-fold diluted culture fluids were added to the monolayer and incubated at 37oC 
and 5% CO2 for an hour with gentle shaking every 15 minutes. After an hour, the cells 
were overlaid with 1.5 ml of 0.6% Bacto Agar (BD) in Modified Eagle Medium (MEM; 
Gibco). The plates were incubated at 37oC for 2 days. The cells were fixed with 10% 
formaldehyde in PBS and stained with 0.02% crystal violet for 30 minutes and plaques 
were counted (73). 
IFNa and IFNβ ELISA 
Supernatants of C8-D1A cells infected with CHIKV 181/25 at an MOI of 5 were 
collected at 12 and 36hpi. The levels of IFNa and IFNβ in the supernatants were 
measured using VeriKine ELISA kits (PBL Assay Science) according to the 
manufacturer’s instructions. 
qRT PCR for Type I IFN, TLRs, and RLRs 
C8-D1A cells and NSC-34 cells either mock-infected or infected with CHIKV WT 
at an MOI of 5 were harvested in RLT buffer (Qiagen). Total RNA was isolated using the 
RNeasy Plus Mini Kit (Qiagen) and cDNA was synthesized using the High Capacity cDNA 
Reverse Transcription Kit (Life Technologies) (73). TaqMan gene expression arrays 
(Integrated DNA Technologies) were used to measure IRF3, IRF7, IFNa, IFNβ, RIG-I, 
MDA5, TLR3, TLR7, TLR 8, TLR9, and Myd88 mRNA levels. The PCR conditions were 
40 cycles of 2 minutes at 50oC, 10 minutes at 95oC, and 1 min at 60oC  performed in 
Applied Biosystems 7500 Real-time PCR machine (73). Relative gene expression was 
determined using the ΔΔCt method using 0-hour control samples, and Gapdh and RPS-
29 were used for normalizing type I IFN, TLR, and RLR mRNA expression.  
 62 
Western Blot Analysis of Protein Expression 
C8-D1A and NSC34 cells were infected with WT at an MOI of 5 or mock-infected 
and incubated at 37oC for various times. At selected time points, the cells were lysed in 
RIPA buffer (50 mM Tris (pH 8), 1 % Triton X-100, 0.1 % of SDS, 150 mM NaCl, 1 mM 
EDTA, and 0.5 % Na3VO42H2O) supplemented with protease and phosphatase inhibitors 
(Sigma) (73) on ice for 30 minutes followed by centrifuging 15,200 x g for 10 min to collect 
the supernatant containing proteins. The Dc protein assay (Bio-Rad) was performed to 
estimate total protein in lysates with BSA as the standard.  15 to 20 µg of protein were 
loaded onto a 10% polyacrylamide gel, separated via electrophoresis, and transferred to 
nitrocellulose membranes. The membranes were blocked with 5% skim milk in PBS at 
RT followed by incubating overnight at 4oC with polyclonal rabbit antibodies to CHIKV 
nsP1, nsP2, nsP3 (1:10000), nsP4 (1:200) (73,90), mouse MAb E2 structural proteins 
(1:1000; CHK-187 11A4. F1.F4) (73), RIG-I, MAVS, phospho-TBK1, TBK1, phospho-
IRF3, IRF3, phospho-IRF7 (1:1000; Cell Signaling Technologies), MDA5, IRF7 (1:500; 
Abcam), TRAF3 (1:500;R&D Systems) or β actin (1:5000; Millipore) diluted in 5% BSA in 
TBST. Secondary antibodies were HRP-conjugated anti-mouse, anti-rabbit, or anti-rat 
IgG (1:1000; Cell Signaling Technologies) diluted in 2% milk and incubated for an hour at 
RT. Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) was 
used to develop the membrane. ImageJ software from NIH was used to analyze the 
densitometry of immunoblots from three to five independent experiments. 
Statistical Analysis 
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Prism 8 (GraphPad) was used for two-way ANOVA tests to calculate significant 
differences between different infections at a single time point. All results are shown as 























Compared to Neurons Astrocytes Produce More Infectious Viruses and Initiate 
Viral Protein Synthesis Earlier. 
To assess differences in CHIKV replication between the astrocytes and neurons, 
the same number of neuronal NSC34 and astrocyte C8-D1A cells were infected with 
CHIKV 181/25 (WT) and virus production was measured using plaque assays (Fig. 3.1B) 
and cell viability was assessed using trypan blue exclusion (Fig. 3.1A). C8-D1A cells 
produced more infectious virus than NSC34 from 6hpi (P<0.001) onwards. Peak virus 
production was at 24hpi with higher viral titers in C8-D1A cells (P<0.001) but similar titers 
at 36hpi. Viability of C8-D1A cells was better at 6hpi (P<0.05), 12hpi (P<0.001), and 24hpi 
(P<0.01) than NSC34 cells. At 36hpi both viability and titer were decreased (P<0.0001). 
To determine whether viral protein translation is affected by cell type, a similar 
number of NSC34 and C8-D1A cells were infected with WT CHIKV at an MOI of 5. 
Lysates were immunoblotted for nsP1, nsP2, nsP3, nsP4 and E2 glycoprotein (Fig. 3.2A). 
Infected C8-D1A cells produced detectable amounts of viral proteins by 6hpi (nsP1, P < 
0.01); (nsP2, P < 0.0001); (nsP3, P < 0.001); (nsP4, P < 0.001); (E2, P < 0.05) while viral 
protein production by NSC34 cells was not detected until 12hpi. (Fig. 3.2B). At later time 
points, amounts of viral protein synthesized by astrocytes slightly, but not significantly, 
higher than neurons.  
Phosphorylation of IRF3 Leads to More Type I IFN Production in Astrocytes. 
To compare activation of the type I IFN response in neurons and astrocytes, a 
similar number of NSC34 and C8-D1A cells were infected with CHIKV at MOI 5 and the 
mRNA expression of several immune factors were determined by qRT-PCR.  There was 
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no change in levels of Ifnα and Ifnβ in neurons compared to mock-infected cells, whereas 
in astrocytes both Ifnα and Ifnβ increased with peaks at 24hpi and 36hpi (P < 0.0001) 
(Fig. 3.3A and Fig. 3.3B). Levels of type I IFN protein produced by CHIKV-infected cells 
were determined by ELISA.  IFNa was detectable by 12hpi and  IFNb by 6hpi after 
infection of C8-D1A cells (adapted from Fig 2.8, Fig 3.3C) (P < 0.0001). However, type I 
IFN protein was not detectable at any time after infection of NSC34 cells (73).  
IRF3 and IRF7 are the fundamental transcriptional regulators of the type I IFN 
response to viral infection. Expression of Irf3 in neurons and astrocytes did not change 
after infection while Irf7 increased from 12hpi onwards, as compared to mock-infected 
cells, only in astrocytes (P<0.0001) (Fig. 3.3D and Fig. 3.3E). To assess activation of 
IRFs during infection, lysates from NSC34 and C8-D1A cells infected with WT CHIKV at 
an MOI of 5 were immunoblotted for phospho-IRF3, total IRF3, phospho-IRF7, and total 
IRF7 (Fig. 3.4). Phosphorylation of IRF7 was not detected until 24hpi and at 36hpi, C8-
D1A cells had more phosphorylated IRF7 than NSC34 cells (P < 0.0001) (Fig. 3.4A and 
Fig. 3.4B). Phosphorylation of IRF3 gradually increased from 12hpi to 36hpi in astrocytes 
(P < 0.0001) but not in neurons (Fig. 3.4C and Fig. 3.4D). Although transcript levels of 
IRF7 increased, the type I IFN response in astrocytes is mainly regulated by activation of 
IRF3 . 
RIG-I Like Receptor pathway is Activated in Astrocytes upon Poly (I:C) Treatment 
Leading to Phosphorylation of IRF7 but not in Neurons. 
 To determine the role of the RIG-I Like Receptor pathway in the induction of type 
I IFN production by astrocytes and not neurons, both cells were treated with either 
universal type I IFN A/D or the synthetic double-stranded RNA analog poly (I:C). 
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Expression of RLRs and their downstream mediators was tested by immunoblotting (Fig 
3.5). When treated with low molecular weight (LMW) poly I:C (length between 0.2kb to 
1kb) and high molecular weight (HMW) poly I:C (length between 1.5kb to 8kb) astrocytes 
increased expression of RIG-I and MDA5, phosphorylated TBK-1 and IRF7. MAVS and 
TRAF3 expression and phosphorylation of IRF3 was constitutive in C8-D1A cells. 
However, poly (I:C) treatment of neurons did not activate any components of the RLR 
signaling pathway, although MAVS and TRAF3 were constitutively expressed (Fig 3.5).  
Treatment with universal type I IFN A/D increased expression of RIG-I in both cells 
while MDA5 activation was more pronounced in astrocytes than in neurons.  
Phosphorylation of IRF3 by treatment with universal type I IFN A/D was more pronounced 
in astrocytes than in neurons, whereas phosphorylation of IRF7 compared to mock-
treated cells did not change in either cell line (Fig 3.5). Additional experiments are needed 
to identify why activation of IRF3 occurs in astrocytes but not in neurons. 
RIG-I Like Receptor Pathway in Astrocytes is Activated Early upon Infection 
Compared to Neurons. 
 To determine which innate immune response is responsible for the 
phosphorylation of IRF3 and activation of type I IFN by CHIKV infection, C8-D1A and 
NSC34 cells were infected with WT CHIKV at an MOI of 5, and mRNA levels were 
measured by qRT-PCR and protein levels by immunoblots (Fig. 3.6A and B). Rig-i mRNA 
was increased in infected C8-D1A cells by 6hpi (P<0.0001) and at 12hpi (P<0.01), 
whereas in infected NSC34 cells an increase was not detectable until 36hpi (P<0.001). 
Mda5 mRNA was increased only in infected C8-D1A cells from 6hpi (P<0.0001) through 
24hpi (P<0.0001). RIG-I receptor protein increased in CHIKV infected astrocytes 
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compared to the mock but in neurons this was observed only at 24hpi (Fig. 3.6C and Fig. 
3.6D). The activation of the adaptor protein MAVS with appearance of a 52kDa cleavage 
product from the parent 75kDa at 24hpi and 36hpi was apparent in astrocytes, but not in 
neurons. There was less phosphoTBK-1 in infected astrocytes at 24hpi and 36hpi 
compared to mock-infected cells (Fig. 3.6C).  
Toll-Like Receptor Pathway upon Infection in Astrocytes. 
To determine whether the toll-like receptor pathway is involved in innate immune 
response upon CHIKV infection in astrocytes and neurons, C8D-1A and NSC34 cells 
were infected at an MOI of 5 and mRNA levels of Tlr3, Tlr7, Tlr9, and Myd88 were 
measured by qRT-PCR. (Fig. 3.7). Expression of Tlr3 (P<0.01) and Myd88 (P<0.0001) in 
astrocytes peaked at 6 hpi, but not in neurons. Expression of Tlr7 and Tlr9 was not 
modulated in either cell line by infection. More experiments must be done to understand 








Figure 3.1 Cell Viability and Infectious Virus Produced after CHIKV WT Infection of 
Astrocytes and Neurons. (A) Cell viability was measured by trypan blue exclusion after 
infection of C8-D1A and NSC-34 cells with CHIKV 181/25 (WT) at an MOI of 5. (B) 
Supernatants of C8-D1A cells and NSC-34 cells infected with WT were serially diluted 
and plated on Vero cells and plaque formation assessed. The data represent the mean ± 
SD from three independent experiments. ⋆ P < 0.05, ⋆⋆ P < 0.01, ⋆⋆⋆ P < 0.001, ⋆⋆⋆⋆ P 
< 0.0001 (C8-D1A WT vs NSC-34 WT). 
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Figure 3.2 Synthesis of CHIKV Proteins by Infected Astrocytes and Neurons. 
Lysates from C8-D1A and NSC-34 cells infected with CHIKV 181/25 (WT) at an MOI of 5 
were immunoblotted with antibodies to nsP1, nsP2, nsP3 nonstructural proteins, E2 
structural protein, and β-actin. (A) A representative image from three independent 
experiments. (B) Quantification by densitometry of viral protein normalized to actin from 
three independent experiments. Data illustrate the mean ± SD. ⋆ P < 0.05, ⋆⋆ P < 0.01, 
⋆⋆⋆ P < 0.001, ⋆⋆⋆⋆ P < 0.0001 (C8-D1A WT vs NSC-34 WT). 
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Figure 3.3 Type I IFN response by CHIKV-infected Astrocytes and Neurons. NSC 34 
and C8-D1A cells were either mock-infected or infected with CHIKV 181/25 and RNA was 
isolated, and cDNA synthesized. Real-time PCR was performed for Ifnɑ (A), Ifnβ (B), Irf3 
(D), and Irf7 (E) to determine changes in gene expression. Ct value for each transcript 
was normalized to Gapdh. Fold change in expression was calculated relative to 0-hour 
mock-infected samples. Data represent the average ± SD. ⋆⋆⋆⋆ P < 0.0001 (C8-D1A WT 
vs NSC-34 WT). (C) Supernatants of C8-D1A cells infected with CHIKV 181/25 (WT) were 
collected and type I IFN level was measured by ELISA. Data represent the average ± SD. 
⋆⋆⋆ P < 0.001, ⋆⋆⋆⋆ P < 0.0001 (IFNɑ; C8-D1A Mock-infected vs. C8-D1A WT); ^^^^ P < 







Figure 3.4 Phosphorylation of IRF3 and IRF7 in Astrocytes and Neurons After 
CHIKV Infection. Lysates from C8-D1A cells and NSC-34 cells infected with CHIKV 
181/25 (WT) at an MOI of 5 were immunoblotted for phospho IRF3, IRF3, phospho IRF7, 
IRF7, and β actin. (A) A representative image from three independent experiments for 
IRF7 protein expression. (B) The ratio of phosphoIRF7 to total IRF7 was quantified by 
densitometry and normalized to β actin. (C) A representative image from three 
independent experiments for IRF3 protein expression. (D) The ratio of phospho IRF3 to 
total IRF3 was quantified by densitometry and normalized to β actin. ⋆⋆⋆⋆ P < 0.0001 
(C8-D1A WT vs NSC-34 WT). 
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Figure 3.5 RLR Pathway activation by IFN or Poly (I:C) Treatment of Neurons and 
Astrocytes To activate antiviral PRRs related to Type I IFN, C8-D1A and NSC34 cells 
were treated with 2µl of universal type I IFN (100U/ml) or 10µl of LMW and HMW poly 
(I:C) (1μg/ml) in DMEM containing 1% FBS. 24 hours after the treatment, lysates were 
collected and immunoblots were performed to determine RLR pathway receptor and 








Figure 3.6 RLR Pathway mRNA and Protein in CHIKV-Infected Astrocytes and 
Neurons NSC-34 and C8-D1A cells were either mock-infected or infected with CHIKV 
181/25 at MOI 5 and RNA was isolated, and cDNA synthesized. Gene expression for Rig-
i (A) and Mda5 (B) was determined by real-time PCR and Ct values normalized to Gapdh. 
Fold change of expression was calculated by comparison to the 0-hour mock-infected 
samples. Data show the average ± SD. ⋆⋆ P < 0.01, ⋆⋆⋆ P < 0.001, ⋆⋆⋆⋆ P < 0.0001 (C8-
D1A WT vs NSC-34 WT). (C,D) Lysates from C8-D1A cells and NSC-34 cells infected 
with CHIKV 181/25 (WT) at an MOI of 5 were immunoblotted for RIG-I, MAVS, TRAF3, 
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phospho TBK1, TBK1, and β actin. (C) A representative image from three independent 
experiments. (D) Quantification of RIG-I protein level by densitometry and normalized to 
actin level from three independent experiments. Data demonstrate the mean ± SD.  
 
 
Figure 3.7 Expression of TLR mRNAs by CHIKV-Infected Neurons and Astrocytes. 
NSC-34 and C8-D1A cells were either mock-infected or infected with CHIKV 181/25 at 
an MOI of 5 and RNA was isolated, and cDNA synthesized. Gene expression for Tlr3 (A), 
Tlr7 (B), Tlr9 (C), and Myd88 (D) was determined by real-time PCR and Ct values 
normalized to Gapdh. Fold change in expression was calculated by comparision to the 0-
hour mock-infected samples. Data show the average ± SD. ⋆⋆ P < 0.01, ⋆⋆⋆⋆ P < 0.0001 







Innate immunity is the first line of defense against viral infections.  The main roles 
for innate immunity are identification and restriction of virus replication and activation of 
the adaptive immune system (47). Early detection of virus is fundamental for activation of 
anti-viral gene and proteins. TLRs, RLRs, and NLRs are the main PRRs for detection of 
viral genomes within cells. While the NLR cascade produces inflammatory cytokines like 
IL1β, TLR and RLR pathways activate IRF3 and IRF7 to upregulate IFNα and IFNβ (50). 
These type I IFNs bind to receptors to activate its own cells and nearby cells through the 
Jak/Stat pathway to induce transcription of more antiviral ISGs (54).  
In mice model CHIKV antigens are found in both neurons and astrocytes (26, 27). 
In this study we show that astrocytes produce 3-100 times more infectious virus than 
neurons (Fig. 3.1 and Fig. 2.1). This correlates with earlier and greater translation of viral 
nonstructural and structural proteins by astrocytes (Fig. 3.2).  
Alphavirus infection increases expression of interferon stimulated PARPs in CNS 
tissues of mice and in astrocytes, whereas in neuronal cells PARPs are activated for ADP 
ribosylation of proteins without increased mRNA expression. Upon infection, astrocytes 
produce type I IFN (Fig. 2.8 and Fig. 3.3A) while neuronal cells do not (70). Animal studies 
of other neurotrophic viruses have also shown that infected astrocytes rapidly produce 
type I interferon to restrict virus replication and cytolysis (92). IFN receptor signaling 
stimulates production of ISGs to restrict and regulate viral blood brain barrier entry (93). 
While the TLR pathway leads to the phosphorylation of IRF7, the RLR pathway 
stimulates phosphorylation of both IRF3 and IRF7. In the current study we demonstrated 
that neurons could activate only IRF7, whereas astrocytes activated both IRF3 and IRF7 
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(Fig. 3.4). Transcript levels of Rig-I and Mda5 in astrocytes increase after infection, while 
in neurons only Rig-I increases at later time points. To mimic the dsRNA intermediate 
formed during infection, astrocytes and neurons were treated with synthetic dsRNA (Fig. 
3.5). While astrocytes made RIG-I and MDA5 proteins, neurons did not (Fig. 3.6). 
Therefore, RLRs are the main signaling pathway leading to type I IFN production by 
astrocytes and are deficient in neurons.  
In summary, MDA-5 and RIG-I detected the dsRNA of CHIKV in astrocytes, but 
not in neurons. These RLRs activated IRF3 and induced IFNβ early after infection in 
astrocytes. IFNβ then induced production of more IRF7 and other ISGs. Although RLR 
activation lead to restriction of virus replication, unexpectedly, more viral proteins and 
infectious virus were produced by astrocytes than neurons. More experiments will be 
required to determine why virus replication is facilitated rather than restricted in astrocytes 
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